BioPharma-Reporter.comUCL spin-out aims to smuggle antibodies across the blood-brain barrierBioPharma-Reporter.comA collaboration involving academia and industry is to develop new ways of delivering antibodies to the brain using molecular envelop techn…
10 Applications of Monoclonal AntibodiesLabmate OnlineMonoclonal antibodies, or mAbs, are antibodies that have been developed and produced from the same identical parent immune cell. As such, they can be developed and honed by scientists to target and …
Pharmazeutische Zeitung onlineMS: Neue Therapeutika in SichtPharmazeutische Zeitung onlineDaclizumab, das bereits als Immunsuppressivum nach Organtransplantation auf dem Markt war, richtet sich gegen CD25-Proteine am Interleukin-2-Rezeptor und beeinflu…
Medical Daily |
Peptide antibodies hit immune-response-stifling MDSCs without harming other …
News-Medical.net Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumors in preclinical experiments, according to a paper published online by Nature Medicine. “We … New Cancer Immunotherapy Targets Cells That Block The Immune SystemMedical Daily |
New Vision |
Scientists find rare group of children who are naturally immune to …
New Vision Prof Kurtis said, “We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children. Tests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine. The … New hope in fight against malariaNews24 Scientists uncover potential vaccine candidateBusiness Recorder Breakthrogh malaria vaccine under develomentDelhi Daily News The Westside Story all 18 news articles » |
The effect of rituximab therapy on immunoglobulin levels in patients with …7thSpace Interactive (press release)Methods: We performed a single centre retrospective review of 177 patients with multisystem autoimmune disease receiving rituximab between …
|
Vaccines and Biologics: Questions Remain
MedPage Today Inadequate protection after influenza vaccination also has been seen among patients receiving the B-cell depleting agent rituximab (Rituxan), with particularly low responses being seen among patients whose B cells are fully depleted. Therefore, “it … |
Daily MailScientists create antibody that blocks pain and itchinessGeekLee used antibodies to capture the channel proteins for study, but he got to wondering if it might be possible to create an antibody to inhibit the function of the channel in living…
Drug Discovery & Development |
EU Committee Backs Roche Leukemia Drug Combo
Drug Discovery & Development … without their disease worsening (progression free survival; PFS) compared to chlorambucil alone and compared to MabThera (rituximab) plus chlorambucil while also increasing the depth of remissions as measured by Minimal Residual Disease (MRD). |
Antibodies to PfSEA-1 block parasite egress from RBCs and protect against …Science Careers Blog (subscription)Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Dipak K. Raj1,; Christian P. Nixon1,; Christina…